Herbal Doctor Remedies New Life recall — FDA D-1146-2020
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
Browse the newest complete recall records currently stored from FDA enforcement reports and NHTSA vehicle campaigns. “Latest” refers to the newest source-dated record in this database, not the timestamp of our last API check.
The newest recall records with useful source details are listed here.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
Firm is recalling 46 lots of various products because of a lack of sterility assurance.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
Firm is recalling 46 lots of various products because of a lack of sterility assurance.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
Firm is recalling 46 lots of various products because of a lack of sterility assurance.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
Firm is recalling 46 lots of various products because of a lack of sterility assurance.
Firm is recalling 46 lots of various products because of a lack of sterility assurance.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level
Firm is recalling 46 lots of various products because of a lack of sterility assurance.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs
Browse recent months with enough recall history for useful comparison.